Steven C. Gilman net worth and biography

Steven Gilman Biography and Net Worth

Director of Vericel

Dr. Steven Gilman has been a member of the Vericel Board of Directors since 2015. Dr. Gilman served as the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation until his retirement in April 2019. He previously served as Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals from September 2010 until its acquisition by Merck & Co., in January 2015. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and Chief Executive Officer of ActivBiotics, Inc., a privately-held biopharmaceutical company. Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles, including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development and has also held scientific, business, and academic appointments at Wyeth Pharmaceuticals, Inc., Cytogen Corporation, Temple Medical School, and Connecticut College. Dr. Gilman currently serves on the boards of directors of ContraFect Corporation, SCYNEXIS, Inc., Akebia Therapeutics, Inc. and Momenta Pharmaceuticals, Inc. Dr. Gilman earned a B.A. in microbiology from Miami University of Ohio and Ph.D. and M.S. degrees in microbiology from Pennsylvania State University. He is an author of over 60 publications and seven U.S. patents.

What is Steven C. Gilman's net worth?: The estimated net worth of Steven C. Gilman is at least $650,210.00 as of October 16th, 2024. Dr. Gilman owns 11,000 shares of Vericel stock worth more than $650,210 as of November 23rd. This net worth approximation does not reflect any other investments that Dr. Gilman may own. Learn More about Steven C. Gilman's net worth.
How do I contact Steven C. Gilman?: The corporate mailing address for Dr. Gilman and other Vericel executives is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. Vericel can also be reached via phone at (617) 588-5555 and via email at [email protected]. Learn More on Steven C. Gilman's contact information.
Has Steven C. Gilman been buying or selling shares of Vericel?: Within the last three months, Steven C. Gilman has sold $476,614.43 in Vericel stock. Most recently, Steven C. Gilman sold 5,833 shares of the business's stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a transaction totalling $241,252.88. Following the completion of the sale, the director now directly owns 11,000 shares of the company's stock, valued at $454,960. Learn More on Steven C. Gilman's trading history.
Who are Vericel's active insiders?: Vericel's insider roster includes Sean Flynn (VP), Steven Gilman (Director), Michael Halpin (COO), Jonathan Hopper (Insider), and Paul Wotton (Director). Learn More on Vericel's active insiders.
Are insiders buying or selling shares of Vericel?: During the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 176,650 shares worth more than $7,927,426.06. The most recent insider tranaction occured on October, 16th when CEO Dominick Colangelo sold 17,500 shares worth more than $724,150.00. Insiders at Vericel own 5.2% of the company. Learn More about insider trades at Vericel.
Information on this page was last updated on 10/16/2024.

Steven C. Gilman Insider Trading History at Vericel

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/16/2024	Sell	5,833	$41.36	$241,252.88	11,000
10/2/2024	Sell	5,833	$40.35	$235,361.55	11,000
4/29/2022	Sell	900	$30.94	$27,846.00	5,200
11/29/2021	Sell	5,000	$39.17	$195,850.00
10/27/2021	Sell	5,000	$50.57	$252,850.00
9/30/2021	Sell	5,000	$48.85	$244,250.00
5/1/2019	Sell	7,500	$16.81	$126,075.00
2/28/2019	Sell	7,500	$18.02	$135,150.00
12/3/2018	Sell	8,500	$17.75	$150,875.00	8,500
9/4/2018	Sell	9,000	$12.03	$108,270.00	9,000

Steven C. Gilman Buying and Selling Activity at Vericel

Vericel Company Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $59.11

$56.52

$60.16

50 Day Range

MA: $46.13

$40.05

$59.11

2 Week Range

Now: $59.11

$32.31

$60.15

Volume

603,389 shs

Average Volume

431,699 shs

Market Capitalization

$2.92 billion

P/E Ratio

985.33

Dividend Yield

N/A

Beta

1.66

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.